Featured Research

from universities, journals, and other organizations

St. John's Wort Does Not Appear Effective For Treating ADHD In Children And Teens

Date:
June 10, 2008
Source:
JAMA and Archives Journals
Summary:
Children and teens with attention-deficit/hyperactivity disorder who were treated with the herb St. John's wort did not have any greater improvement in ADHD symptoms compared to those who received placebo.

Children and teens with attention-deficit/hyperactivity disorder (ADHD) who were treated with the herb St. John's wort did not have any greater improvement in ADHD symptoms compared to those who received placebo.

ADHD affects 3 to 12 percent of children in the United States. Up to 30 percent of these children do not respond to pharmaceutical medications or have adverse effects such as nausea, insomnia, or weight loss from the medications, according to background information in the article. "For these reasons, many parents seek complementary or alternative medicine for their children with ADHD. Complementary or alternative medicine treatments used for pediatric ADHD include massage, dietary changes, dietary supplements, and herbal treatments. In the United States, the most common herbal treatments used by children with ADHD are St John's wort, Echinacea species, and Ginkgo biloba," the authors write.

Wendy Weber, N.D., Ph.D., M.P.H., of Bastyr University, Kenmore, Wash., and colleagues conducted a clinical trial of St. John's wort (Hypericum perforatum) with 54 children and adolescents with ADHD, age 6 to 17 years, to determine whether this agent was effective in lessening the severity of ADHD symptoms. Twenty-seven participants were randomly assigned to receive 300 mg of H perforatum standardized to 0.3 percent hypericin (a compound derived from H perforatum) and 27 participants received a matched placebo, three times daily for eight weeks. Other medications for ADHD were not allowed during the trial.

The researchers found that there were no significant differences between the two groups in the change in ADHD rating scale scores from the start of the trial to week 8 and in change in scores rating inattentiveness and hyperactivity. There was also no difference in the proportion of participants who were rated as much or very much improved regarding ADHD symptoms on another measurement scale. No statistically significant difference was found between the two groups in the proportion of participants who experienced 1 or more rash, nausea/vomiting, headache, or sunburn during the trial.

"To our knowledge, this is the first placebo-controlled trial of H perforatum in children and adolescents. The results of this study suggest that administration of H perforatum has no additional benefit beyond that of placebo for treating symptoms of child and adolescent ADHD," the authors write.

Editorial: Quality of Efficacy Research in Complementary and Alternative Therapies

In an accompanying editorial, Eugenia Chan, M.D., M.P.H., of Children's Hospital Boston and Harvard Medical School, writes that conducting randomized controlled trials of complementary and alternative therapies can pose challenges.

"... randomizing participants may be difficult or impossible when the therapy to be evaluated relies on participants' belief in the treatment or relationship with the practitioner. Use of placebo and blinding may be difficult in therapies such as acupuncture, yoga, psychotherapy, or surgery, although techniques such as placebo needles that do not actually enter the skin have been developed. Even when a plausible placebo can be used, placebo and expectation effects can be very large in both complementary and alternative medicine and conventional interventions and may be part of the mechanism of treatment efficacy."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wendy Weber; Ann Vander Stoep; Rachelle L. McCarty; Noel S. Weiss; Joseph Biederman; Jon McClellan. Hypericum perforatum (St John's Wort) for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Randomized Controlled Trial. JAMA, 2008;299(22):2633-2641 [link]

Cite This Page:

JAMA and Archives Journals. "St. John's Wort Does Not Appear Effective For Treating ADHD In Children And Teens." ScienceDaily. ScienceDaily, 10 June 2008. <www.sciencedaily.com/releases/2008/06/080610161250.htm>.
JAMA and Archives Journals. (2008, June 10). St. John's Wort Does Not Appear Effective For Treating ADHD In Children And Teens. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2008/06/080610161250.htm
JAMA and Archives Journals. "St. John's Wort Does Not Appear Effective For Treating ADHD In Children And Teens." ScienceDaily. www.sciencedaily.com/releases/2008/06/080610161250.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins